Author:
Levin-Epstein Rebecca,Qiao-Guan George,Juarez Jesus E.,Shen Zhouhuizi,Steinberg Michael L.,Ruan Dan,Valle Luca,Nickols Nicholas G.,Kupelian Patrick A.,King Christopher R.,Cao Minsong,Kishan Amar U.
Reference45 articles.
1. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial;Widmark;Lancet,2019
2. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline;Morgan;Pract Radiat Oncol,2018
3. Prostate cancer NCCN guidelines version 4 20193673
MohlerJL
HurwitzM
RicheyS
NCCN Guidelines1632019
4. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies;Jackson;Int J Radiat Oncol Biol Phys,2019
5. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial;Brand;Lancet Oncol,2019
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献